Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 75

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 2
Chunk 75
---
    scope, rate of progress and expenses of preclinical studies and clinical trials and other research and development activities;

    ●
    potential
    safety monitoring and other studies requested by regulatory agencies; and

    ●
    significant
    and changing government regulation.

The
process of conducting the necessary clinical research to obtain FDA and other regulatory approval is costly and time consuming and the
successful development of product candidates is highly uncertain. These risks and uncertainties associated with our research and development
projects are discussed more fully in Part II. Item 1A. “Risk Factors - We expect to continue to incur significant research and
development expenses and other operating expenses, which may make it difficult for us to attain profitability.” As a result
of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research
and development projects, or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our
product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.

General
and Administrative Expenses

General
and administrative expenses include compensation, employee benefits, and stock-based compensation, finance administration and human resources,
facility costs (including rent), professional service fees, and other general overhead costs to support our operations.

We
expect our general and administrative expenses to increase for the foreseeable future as we continue to increase our headcount to support
our research and development activities and operations generally, the growth of our business and, if any of our product candidates receive
marketing approval, commercialization activities. We also expect to continue to incur expenses as a result of operating as a public company,
including expenses related to compliance with the rules and regulations of the SEC, additional director and officer insurance expenses,
investor relations activities, and other administrative and professional services.

Other
Income, Net

Other
income, net includes interest earned on deposits and investments and other items of income and gain and loss that are incidental to the core operations of the Company.

3

Results
of Operations

Three
months ended June 30, 2025 compared to three months ended June 30, 2024

The
following tables set forth our results of operations for the three months ended June 30, 2025 and 2024 and the relative dollar change
between the two periods.

    Three months ended  

    June 30,  
    Change 

    2025  
    202